

# IMMUNIZATION PROGRAM DATA

Regional and Country Profiles 2022  
(Data as of October 2023)



World Health  
Organization

Western Pacific Region

# IMMUNIZATION PROGRAM DATA

Regional and Country Profiles 2022  
(Data as of October 2023)



**World Health  
Organization**

---

Western Pacific Region

© World Health Organization 2023

ISBN 978 92 9061 980 2

Some rights reserved.

This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition". Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules>).

*Suggested citation.* Immunization program data: regional and country profiles 2022. Manila: World Health Organization Regional Office for the Western Pacific; 2022. Licence: CC BY-NC-SA 3.0 IGO.

*Cataloguing-in-Publication (CIP) data.* 1. Immunization programs - statistics and numerical data. 2. Data management. I. World Health Organization Regional Office for the Western Pacific. (NLM Classification: WA115).

*Sales, rights and licensing.* To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>. For WHO Western Pacific Regional Publications, request for permission to reproduce should be addressed to Publications Office, World Health Organization, Regional Office for the Western Pacific, P.O. Box 2932, 1000, Manila, Philippines, Fax. No. (632) 8521-1036, email: [wpropuballstaff@who.int](mailto:wpropuballstaff@who.int).

*Third-party materials.* If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

*General disclaimers.* The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

# CONTENTS

<b>Acronyms and notes</b>	1
<b>Regional profile</b>	
Summary	5
Immunization coverage	6
<b>Country profiles</b>	
Non-Pacific island countries and areas	
Australia	10
Brunei Darussalam	12
Cambodia	14
China	16
China, Hong Kong SAR	18
China, Macao SAR	20
Japan	22
Lao People's Democratic Republic	24
Malaysia	26
Mongolia	28
New Zealand	30
Papua New Guinea	32
Philippines	34
Republic of Korea	36
Singapore	38
Viet Nam	40
Pacific island countries and areas	
American Samoa	44
Cook Islands	46
Fiji	48
French Polynesia	50
Guam	52
Kiribati	54
Marshall Islands	56
Micronesia, Federated States of	58
Nauru	60
New Caledonia	62
Niue	64
Northern Mariana Islands, Commonwealth of the	66
Palau	68
Samoa	70
Solomon Islands	72
Tokelau	74
Tonga	76
Tuvalu	78
Vanuatu	80
Wallis and Futuna	82

## ACRONYMS AND NOTES

<b>AEFI</b>	adverse events following immunization
<b>AFP</b>	acute flaccid paralysis
<b>BCG</b>	Bacille Calmette-Guerin vaccine
<b>bOPV</b>	bivalent oral poliovirus vaccine
<b>CRS</b>	congenital rubella syndrome
<b>cVDPV</b>	circulating vaccine-derived poliovirus
<b>DHS</b>	demographic health survey
<b>DQSA</b>	data quality self-assessment
<b>DT</b>	diphtheria and tetanus toxoid, children's dose
<b>DTaP</b>	diphtheria and tetanus toxoid with acellular pertussis vaccine
<b>DTP</b>	diphtheria and tetanus toxoid with pertussis vaccine
<b>DTwP</b>	diphtheria and tetanus toxoid with whole cell pertussis vaccine
<b>eJRF</b>	WHO/UNICEF Electronic Joint Reporting Form for Immunization
<b>EVM</b>	effective vaccine management
<b>FIC</b>	fully-immunized child
<b>HBsAg</b>	hepatitis B surface antigen
<b>HepA</b>	hepatitis A vaccine
<b>HepB</b>	hepatitis B vaccine
<b>HepB BD</b>	hepatitis B vaccine birth dose
<b>Hib</b>	<i>Haemophilus influenzae</i> type b vaccine
<b>HPV</b>	human papillomavirus vaccine
<b>IPV</b>	inactivated polio vaccine
<b>IPVf</b>	inactivated polio vaccine fractional dose
<b>IR</b>	incidence rate
<b>JE</b>	Japanese encephalitis
<b>LMIC</b>	low- and middle-income countries
<b>MCV</b>	measles-containing vaccine
<b>MenA ps</b>	meningococcal A polysaccharide vaccine
<b>MenAC ps</b>	meningococcal AC polysaccharide vaccine
<b>MenACYW conj</b>	meningococcal ACYW-135 conjugate vaccine
<b>MenACYW ps</b>	meningococcal ACYW-135 polysaccharide vaccine
<b>MenC conj</b>	meningococcal C conjugate vaccine
<b>MICS</b>	multiple indicator cluster survey
<b>MMR</b>	measles, mumps and rubella vaccine
<b>MMRV</b>	measles, mumps, rubella and varicella vaccine
<b>MNT</b>	maternal and neonatal tetanus
<b>MR</b>	measles and rubella vaccine
<b>NA</b>	not applicable
<b>ND</b>	no data
<b>NIP</b>	national immunization programme
<b>NITAG</b>	national immunization technical advisory group
<b>NUV</b>	new and underutilized vaccines and biologicals
<b>OPV</b>	oral poliovirus vaccine

<b>PAB</b>	protected at birth
<b>PCV</b>	pneumococcal conjugate vaccine
<b>Pol3</b>	third dose of polio vaccine
<b>PPV</b>	pneumococcal polysaccharide vaccine
<b>RCV</b>	rubella-containing vaccine
<b>RV</b>	rotavirus vaccine
<b>SARS-CoV2</b>	severe acute respiratory syndrome coronavirus 2
<b>SIA</b>	supplementary immunization activity
<b>Td</b>	tetanus and diphtheria toxoid for older children and adults
<b>Tdap</b>	tetanus, diphtheria toxoid, acellular pertussis for older children and adults
<b>TT</b>	tetanus toxoid vaccine
<b>Typhoid conj</b>	typhoid conjugate vaccine
<b>VDPV</b>	vaccine-derived polio virus
<b>VitA</b>	vitamin A supplements
<b>VPD</b>	vaccine-preventable disease
<b>WPV</b>	wild polio virus

#### Explanatory notes:

1. Data sources
  - a. Main source of data is the WHO/UNICEF Electronic Joint Reporting Form (eJRF) on Immunization, unless otherwise specified.
  - b. For immunization coverage, two different sources of data are used: (1) "WHO/UNICEF estimates of national immunization coverage (WUENIC)" which are the official estimates prepared annually by WHO and UNICEF from the coverage data reported by Member States, as well as data reported in published and grey literature; and (2) "Reported coverage" which are the official country estimates, if available; otherwise, national administrative coverage is used.
  - c. For AFP and measles surveillance data, data is taken from monthly country submissions to WHO.
  - d. Population estimates - United Nations World Population Prospects: 2022 Revision
  - e. Financing data - World Bank: World Development Indicators
2. Denominators
  - a. From the 37 countries and areas in the Region, Pitcairn Islands is not included in this publication due to unavailability of data.
  - b. For measles and rubella elimination, Pacific island countries and areas are verified as one group.
  - c. For AFP and measles surveillance indicators, Pacific island countries and areas are considered as one reporting block.
3. Regional coverage is the weighted average based on total population among reporting countries.
4. Zero-dose children is calculated as the difference between the number of under-1 year olds (i.e., surviving infants) and the number of children vaccinated with DTP1; negative values mean that the number of zero-dose children have increased.
5. New and under-utilized vaccines include: Hib, HPV, JE, PCV and rotavirus vaccine. Number of remaining NUV introductions as of 2020 among LMIC was 36.
6. A NITAG is considered "functional" if it satisfies all of the following conditions: with legislative or administrative basis, having a formal written terms of reference, having at least 5 areas of expertise represented in the group, met at least once per year with agenda and background documents distributed, and members required to disclose conflict of interest.